Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Classification ofKRAS-Activating Mutations and the Implications for Therapeutic Intervention
Christian W. Johnson, Deborah L. Burkhart, Kevin M. Haigis
Cancer Discovery (2022) Vol. 12, Iss. 4, pp. 913-923
Open Access | Times Cited: 60

Showing 26-50 of 60 citing articles:

KRAS: Druggable at Last
Benjamin Herzberg, Gulam A. Manji
The Oncologist (2023) Vol. 28, Iss. 4, pp. 283-286
Open Access | Times Cited: 7
Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors
Xuanzheng Xiao, Juanjuan Feng, Jing Ma, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 22, pp. 15524-15549
Closed Access | Times Cited: 7
Mutation Pathogenicity Prediction by a Biology Based Explainable AI Multi-Modal Algorithm
Raizy Kellerman, Omri Nayshool, Ortal Barel, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
Huaying Wang, Lie Lin, Chuqiao Liang, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Targeting KRAS in Pancreatic Cancer
Darren Cowzer, Mohammed Zameer, Michael Conroy, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 11, pp. 1870-1870
Open Access | Times Cited: 12
RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming
Lisa Miller‐Phillips, Eric A. Collisson
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 8, pp. 1088-1101
Closed Access | Times Cited: 6
The Next Generation of KRAS Targeting: Reasons for Excitement and Concern
Neal S. Akhave, Amadeo B. Biter, David S. Hong
Molecular Cancer Therapeutics (2022) Vol. 21, Iss. 11, pp. 1645-1651
Open Access | Times Cited: 9
Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy
Junmin Zhang, Jilei Zhang, Elaine Lai‐Han Leung, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 2, pp. 101-106
Closed Access | Times Cited: 4
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
Elisabetta Puliga, Chiara De Bellis, Sandra Vietti Michelina, et al.
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 473-483
Open Access | Times Cited: 1
Targeting the molecular chaperone CCT2 inhibits GBM progression by influencing KRAS stability
Feihu Zhao, Zhong Yao, Yaquan Li, et al.
Cancer Letters (2024) Vol. 590, pp. 216844-216844
Closed Access | Times Cited: 1
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation
Clement Chung, Godsfavour Umoru
Journal of Oncology Pharmacy Practice (2024)
Closed Access | Times Cited: 1
In Silico Identification of Dysregulated miRNAs Targeting KRAS Gene in Pancreatic Cancer
Asbiel Felipe Garibaldi-Ríos, Luis E. Figuera, Guillermo Moisés Zúñiga‐González, et al.
Diseases (2024) Vol. 12, Iss. 7, pp. 152-152
Open Access | Times Cited: 1
Hypoxia induces extensive protein and proteolytic remodeling of the cell surface in pancreatic adenocarcinoma (PDAC) cell lines
Irene Lui, Katrin Schæfer, Lisa L. Kirkemo, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
The role of silent mutations in KRAS-mutant tumors
Jun Lu, Chao Zhou, Feng Pan, et al.
Chinese Medical Journal (2024)
Open Access | Times Cited: 1
Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes in Human Cancer
Freya Vaeyens, Jan-Patrick Hetzel, Marco Mernberger, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 3
Spontaneously evolved progenitor niches escape Yap oncogene addiction in advanced pancreatic ductal adenocarcinomas
Shigekazu Murakami, Shannon M. White, Alec T. McIntosh, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Clinical Progress of KRAS-targeted Therapies: What next?
Misako Nagasaka, Asfar S. Azmi
Future Medicinal Chemistry (2022) Vol. 14, Iss. 15, pp. 1107-1110
Closed Access | Times Cited: 5
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Mallika Singh, Matthew Holderfield, Bianca J. Lee, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Allosteric site variants affect GTP hydrolysis on Ras
Christian W. Johnson, Susan Fetics, Kathleen P. Davis, et al.
Protein Science (2023) Vol. 32, Iss. 10
Open Access | Times Cited: 2
Fine‐Tuning the Relevance of Molecular Targets to Pediatric Cancer: Addressing Additional Layers of Complexity
Rosane Charlab, Gilbert J. Burckart, Gregory H. Reaman
Clinical Pharmacology & Therapeutics (2022) Vol. 113, Iss. 5, pp. 957-959
Closed Access | Times Cited: 3
KRAS silencing impacts chromatin organization and transcriptional activity in colorectal cancer cells
Flávia Martins, Ana Luísa Machado, Andreia Ribeiro, et al.
Research Square (Research Square) (2024)
Open Access
The MET growth signaling complex drives Alzheimer’s Disease-associated brain pathology in aged Shugoshin 1 mouse cohesinopathy model
Chinthalapally V. Rao, Julie Crane, Ben Fowler, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
KRAS silencing alters chromatin physical organization and transcriptional activity in colorectal cancer cells
Flávia Martins, Ana Luísa Machado, Andreia Ribeiro, et al.
Research Square (Research Square) (2024)
Open Access
Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors
Tomohiro Kondo, Osamu Kikuchi, Yoshihiro Yamamoto, et al.
The Oncologist (2024)
Open Access
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
Dan Zhao, Haiqing Li, Isa Mambetsariev, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access

Scroll to top